ARDX Insider Trading
Insider Ownership Percentage: 4.80%
Insider Buying (Last 12 Months): $4,316,176.94
Insider Selling (Last 12 Months): $5,578,531.89
Ardelyx Share Price & Price History
Current Price: $3.97
Price Change: ▲ Price Increase of +0.01 (0.25%)
As of 05/23/2025 05:00 PM ET
Ardelyx Insider Trading History
Ardelyx Institutional Trading History
Data available starting January 2016
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Read More on Ardelyx
Volume
2,574,219 shs
Average Volume
4,455,239 shs
Market Capitalization
$949.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.76
Who are the company insiders with the largest holdings of Ardelyx?
Ardelyx's top insider investors include:
- David M Mott (Director)
- Michael Raab (CEO)
- Justin A Renz (CFO)
- Laura A Williams (Insider)
- David P Rosenbaum (Insider)
- Robert Blanks (Insider)
- Susan Rodriguez (Insider)
- Eric Duane Foster (Insider)
- Elizabeth A Grammer (Insider)
- Mike Kelliher (Insider)
- Robert Ora Felsch (Insider)
Learn More about top insider investors at Ardelyx.
Who are the major institutional investors of Ardelyx?
Which major investors are selling Ardelyx stock?
During the previous quarter, ARDX stock was sold by these institutional investors:
- Hsbc Holdings PLC
- Rafferty Asset Management LLC
- Knott David M Jr
- Capital Fund Management S.A.
- Pekin Hardy Strauss Inc.
- Algert Global LLC
- XTX Topco Ltd
- Simplex Trading LLC
In the last year, company insiders that have sold Ardelyx company stock include:
- David M Mott (Director)
- Michael Raab (CEO)
- Justin A Renz (CFO)
- Laura A Williams (Insider)
- David P Rosenbaum (Insider)
- Robert Blanks (Insider)
- Susan Rodriguez (Insider)
- Eric Duane Foster (Insider)
Learn More investors selling Ardelyx stock.
Which major investors are buying Ardelyx stock?
Within the previous quarter, ARDX stock was acquired by institutional investors including:
- Millennium Management LLC
- Nuveen LLC
- AQR Capital Management LLC
- Trexquant Investment LP
- Vanguard Group Inc.
- Adage Capital Partners GP L.L.C.
- ADAR1 Capital Management LLC
- Universal Beteiligungs und Servicegesellschaft mbH